Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 73.8 kDa. The protein migrates as 100-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, 0.3M Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human SAPPbeta, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human SAPPbeta, His Tag (Cat. No. APP-H52H5) is more than 90% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sodium Oligomannurarate | GV-971; 971 | Approved | Ocean University Of China, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 九期一 | Mainland China | Alzheimer Disease | Shanghai Greenvalley Pharmaceutical Co Ltd | 2019-11-02 | Parkinson Disease; Cognitive Dysfunction; Alzheimer Disease | Details |
Flutemetamol (18F) | AH-110690; GE-067; 18F-GE067 | Approved | Ge Healthcare | Vizamyl | United States | Contrast agents | Ge Healthcare | 2013-10-25 | Atherosclerosis; Cardiomyopathies; Breast Neoplasms; Contrast agents; Cognitive Dysfunction; Alzheimer Disease; Dementia; Diagnostic agents; Hydrocephalus, Normal Pressure; Cognition Disorders | Details |
Inositol | 4L6452S749 | Approved | Nicosit | Infant, Newborn, Diseases; Precancerous Conditions; Hyperandrogenism; Carcinoma, Non-Small-Cell Lung; Infant, Premature, Diseases; Retinopathy of Prematurity; Lung Neoplasms; Metabolic Diseases; Bronchopulmonary Dysplasia; Anovulation; Diabetic Neuropathies; Insulin Resistance; Glucose Intolerance; Polycystic Ovary Syndrome; Small Cell Lung Carcinoma; Anxiety; Depression | Details | |||||
Immune globulin 10% (Grifols) | KIg-10; TAL-05-0002 | Approved | Bayer AG | Gamunex, Gammaked | United States | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Immunologic Deficiency Syndromes | null | 2003-08-27 | Anxiety Disorders; Corneal Neovascularization; Immunologic Deficiency Syndromes; Kidney Failure, Chronic; Muscular Diseases; Common Variable Immunodeficiency; Neuralgia; Obsessive-Compulsive Disorder; Reflex Sympathetic Dystrophy; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Autoimmune Diseases; Postural Orthostatic Tachycardia Syndrome; Coronavirus Disease 2019 (COVID-19); Agammaglobulinemia; Tibial Fractures; Primary Immunodeficiency Diseases; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
Florapronol (18F) | 18F-FC-119S; 18F-FC-119(S) | Approved | Korea Institute Of Radiological And Medical Sciences, Futurechem | Alzavue | Alzheimer Disease | Details | ||||
Aducanumab | BIIB-037; NI-10; BART | Approved | Neurimmune Ag | ADUHELM | United States | Alzheimer Disease | Biogen Inc | 2021-06-07 | Cognitive Dysfunction; Dementia; Alzheimer Disease | Details |
L-Lysine hydrochloride/Cyanocobalamin/Inositol | Approved | 兴邦 | Malnutrition | Details | ||||||
Immune Globulin Subcutaneous (Human) (Octapharma) | Approved | Octapharma | Cutaquig, Octanorm, Gammanorm | United States | Immunologic Deficiency Syndromes | null | 2018-08-02 | Primary Immunodeficiency Diseases; Dermatomyositis; Immunologic Deficiency Syndromes | Details | |
Florbetaben (18F) | MNI-815; AV-1; ZK-6013443; BAY-949172; 18F-AV-1; 18F-AV1/ZK; AV-1/ZK; BAY 94-9172; UNII-TLA7312TOI | Approved | Piramal | Neuraceq, 欧韦宁 | EU | Alzheimer Disease | Life Radiopharma Berlin Gmbh | 2014-02-20 | Supranuclear Palsy, Progressive; Down Syndrome; Hyponatremia; Immunoglobulin Light-chain Amyloidosis; Contrast agents; Amyloidosis; Alzheimer Disease; Dementia | Details |
Lecanemab | BAN-2401 | Approved | Bioarctic Neuroscience | Leqembi, 乐意保, LEQEMBI | United States | Alzheimer Disease | Eisai Inc | 2023-01-06 | Alzheimer Disease; Cognitive Dysfunction; Dementia | Details |
Florbetapir(18F) | MNI-798; AV-45 | Approved | Eli Lilly And Company | Amyvid | United States | Spasms, Infantile; Rheumatic Diseases; Respiration Disorders; Multiple Sclerosis; Eye Diseases; Collagen Diseases; Skin Diseases; Hypersensitivity | Avid Radiopharmaceuticals Inc | 2012-04-06 | Amyloidosis; Hypersensitivity; Frontotemporal Dementia; Neurodegenerative Diseases; Collagen Diseases; Eye Diseases; Lewy Body Disease; Diagnostic agents; Parkinson Disease; Respiration Disorders; Alzheimer Disease; Rheumatic Diseases; Cognitive Dysfunction; Contrast agents; Spasms, Infantile; Skin Diseases; Multiple Sclerosis; Glioblastoma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Down Syndrome; Chronic Traumatic Encephalopathy; Parkinson Disease; Alzheimer Disease; Cognitive Dysfunction; Frontotemporal Dementia | Details |
Gantenerumab | MAb-31; R-1450; RG-1450; R-04909832 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Alzheimer Disease; Dementia | Details |
Valiltramiprosate | NRM-8499; ALZ-801; BLU-8499 | Phase 3 Clinical | Alzheon Inc | Alzheimer Disease | Details |
Solanezumab | LY-2062430 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease; Dementia; Cognition Disorders | Details |
Birtamimab | NEOD-001 | Phase 3 Clinical | Prothena | Immunoglobulin Light-chain Amyloidosis; Amyloidosis | Details |
Remternetug | LY-3372993 | Phase 3 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
L-clausenamide | Phase 2 Clinical | Guangzhou Nuohao Pharmaceutical Technology Co Ltd, Fuan Pharmaceutical (Group) Co Ltd, Institue Of Materia Medica Chinese Academy Of Medical Science, Qingdao Huanghai Pharmaceutical Co Ltd | Dementia; Cognitive Dysfunction; Memory Disorders | Details | |
Crenezumab | MABT-5102-A; RG-7412; R-7412; RO-5490245 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
11C-BF-227 | 11C-BF-227; [11C]BF-227 | Phase 2 Clinical | Tohoku University | Diagnostic agents | Details |
Pittsburgh Compound B | [11C]PIB; [11C]6-OH-BTA-1; 11C-PIB | Phase 2 Clinical | The University Of Utah, University Of Pittsburgh, Ge Healthcare, Uppsala Universitet | Ovarian Neoplasms; Brain Concussion; Breast Neoplasms; Alzheimer Disease; Alcoholism; Dementia; Parkinson Disease | Details |
CT-1812 | CT-1812; SV-119 | Phase 2 Clinical | Cogrx | Alzheimer Disease; Cognitive Dysfunction; Lewy Body Disease; Macular Degeneration | Details |
[18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
Edonerpic | T-817 MA | Phase 2 Clinical | Toyama Chemical Co Ltd, Fujifilm Group | Alzheimer Disease; Cognitive Dysfunction; Hepatic Insufficiency | Details |
ABvac-40 | ABvac-40 | Phase 2 Clinical | Araclon Biotech Sl | Alzheimer Disease; Cognitive Dysfunction | Details |
PK-051 | PK051; PK-051 | Phase 2 Clinical | PharmaKure Ltd | Alzheimer Disease; Cognitive Dysfunction | Details |
PRI-002 | RD-2; PRI-002 | Phase 2 Clinical | PRInnovation GmbH, Priavoid | Alzheimer Disease; Cognitive Dysfunction | Details |
18F-92 | 18F-92 | Phase 2 Clinical | First Affiliated Hospital Of Fujian Medical University | Alzheimer Disease | Details |
SHR-1707 | SHR-1707 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Alzheimer Disease | Details |
[18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
AD-35 | AD-35 | Phase 2 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Alzheimer Disease | Details |
Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
APH-1105 | APH-1105 | Phase 2 Clinical | Aphios | Dementia; Alzheimer Disease | Details |
RIV-1061-IR | RIV-1061; RIV-1061-IR | Phase 1 Clinical | Revivo Therapeutics | Alzheimer Disease; Cognition Disorders | Details |
A ß antibody Fab | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
RQ-9 | AAT-009; RQ-9; RQ-00000009 | Phase 1 Clinical | Pfizer Inc | Dementia | Details |
ASN-120290 | ASN-561; ASN-90; ASN-120290 | Phase 1 Clinical | Merck Serono | Alzheimer Disease; Parkinson Disease | Details |
MDR-1339 | DBT-1339; MDR-1339 | Phase 1 Clinical | Medifron | Alzheimer Disease | Details |
AV-1959D | AV 1959D; AV-1959D | Phase 1 Clinical | Institute For Molecular Medicine, University Of California, Flinders University | Alzheimer Disease | Details |
ALZ-101 | ALZ-101 | Phase 1 Clinical | Alzinova AB | Alzheimer Disease; Dementia | Details |
PRX-012 | PRX-012 | Phase 1 Clinical | Prothena | Alzheimer Disease | Details |
PMN-310 | huPMN-310; PMN-310 | Phase 1 Clinical | ProMIS Neurosciences Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Multiple System Atrophy | Details |
RP-902 | RP902; RP-902 | Phase 1 Clinical | Risen (Suzhou) Pharma Tech Co Ltd | Alzheimer Disease | Details |
ACU-193 | ACU-193; ACU193 | Phase 1 Clinical | Acumen Pharmaceuticals Inc | Alzheimer Disease | Details |
OAB-14 | OAB-14 | Phase 1 Clinical | Shenyang Pharmaceutical University | Alzheimer Disease | Details |
ALN-APP | Phase 1 Clinical | Sirna Therapeutics Inc | Cerebral Amyloid Angiopathy; Spinocerebellar Degenerations; Alzheimer Disease; Neurodegenerative Diseases | Details | |
BEY-2153 | BEY-2153 | Phase 1 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
Abeta42 antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details | |
Anatabine citrate | RCP-006 | Clinical | Rock Creek, Roskamp Institute | Thyroiditis, Autoimmune; Smoking Cessation; Tobacco Use Disorder; Alzheimer Disease; Inflammation | Details |
123I-ABC-577 | 123I-ABC-577 | Clinical | Nihon Medi-Physics Co Ltd | Diagnostic agents | Details |
Tarenflurbil spraygel (MIKA Pharma) | Clinical | Galen Ltd, Mika Pharma Gmbh | Pain; Arthritis, Rheumatoid; Skin Diseases; Inflammation; Dermatitis, Atopic | Details | |
Procaine Hydrochloride/Vitamin B6/Inositol | Details | ||||
Inositol/Vitamin B1/Vitamin B2 | Details |
This web search service is supported by Google Inc.